Sudden death in hypertrophic cardiomyopathy

Area of Science:

• Cardiology
• Genetics
• Sudden Cardiac Death Research

Background:

• Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death (SD) in young individuals, including athletes.
• Risk stratification for SD in HCM is challenging due to disease heterogeneity and unpredictable arrhythmogenic substrates.
• Identifying candidates for prophylactic device therapy requires careful consideration of multiple risk factors.

Purpose of the Study:

• To evaluate the effectiveness of current risk stratification algorithms for sudden death in hypertrophic cardiomyopathy.
• To assess the role of implantable cardioverter-defibrillators (ICDs) in preventing sudden death in HCM patients.
• To discuss the impact of ICDs on the natural history and management of hypertrophic cardiomyopathy.

Main Methods:

• Review of current risk factor algorithms for sudden death in hypertrophic cardiomyopathy.
• Analysis of implantable defibrillator intervention rates in HCM patients.
• Discussion of clinical judgment in conjunction with risk stratification tools.

Main Results:

• Current risk factor algorithms, combined with physician judgment, effectively identify high-risk HCM patients for defibrillator implantation.
• Implantable defibrillators have demonstrated significant appropriate intervention rates, effectively terminating life-threatening arrhythmias.
• A small subset of HCM patients without conventional risk factors may still be at risk for sudden death.

Conclusions:

• Implantable defibrillators represent a paradigm shift in managing hypertrophic cardiomyopathy, offering the only proven protection against sudden death.
• ICDs have altered the natural history of HCM, potentially enabling normal longevity for affected individuals.
• Prevention of sudden death is a critical, though complex, aspect of contemporary HCM management.